Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and how to wisely invest in this innovative field.

Odyssey Therapeutics Inc. raised $304 million in an upsized US initial public offering priced at the top of a marketed range, along with a private placement.

Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual firms.

(Michael on for Roanna Ruiz), Leerink Partners: "what would constitute a clear signal as a green light to initiate Phase III in 2027?"; President, CEO & Director De Backer: "it's going to really be the totality of the data" and "our goal is pending data, obviously, to start pivotal trials in 2027."

PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer – Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a ...

Fermentation has evolved from a traditional preservation method into a cornerstone of modern food innovation, where the intersection of bioprocess

The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech industry is alive and well. Here are seven top biotech stocks with "overweight" ratings from Morgan Stanley analysts:

Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VIR.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at